To improve tolerance and adherence for PI3K/AKT/mTOR inhibitors, oncology nurses should preemptively provide patients with tools like loperamide for diarrhea and non-drowsy antihistamines for rash, instructing them to use them at the very first sign of symptoms.

Clinical trials with zanidatumab revealed significant diarrhea primarily in the first cycle. The successful management strategy involves mandatory loperamide twice daily for the first seven days to improve tolerability and prevent treatment discontinuation, a crucial implementation pearl.

The side effects of Capivasertib do not occur simultaneously. Rash and diarrhea typically present early, while hyperglycemia manifests later, within the first two months. This staggered onset provides a crucial window for clinicians to manage the initial toxicities before needing to address metabolic effects, simplifying patient care.

A subgroup analysis from Capitello-291 suggests patients treated with capivasertib in the first-line setting experienced less diarrhea and rash than those in later lines. This aligns with a broader trend where heavily pre-treated patients exhibit poorer drug tolerance. This finding supports considering potent targeted agents earlier in the treatment sequence to potentially improve tolerability and outcomes.

The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.

The side effect profile of capivasertib is front-loaded. Key toxicities like diarrhea and rash appear quickly, leading to the majority (63%) of drug discontinuations occurring within the first three months. This highlights a critical window for proactive management and patient education to improve adherence.

When patients experience a consistent pattern of diarrhea, clinicians should move from a reactive, per-episode dosing strategy to a proactive, scheduled regimen of loperamide. This provides better control and prevents symptoms from escalating, with the option to de-escalate as the patient stabilizes.

To manage the significant diarrhea associated with the new drug zanidatumab, a proactive approach is critical. The successful HORIZON-GEA trial protocol included mandatory loperamide twice daily for the first seven days of cycle one, a strategy which effectively managed toxicity without leading to treatment discontinuation.

Real-world use of capivaseratib reveals more challenging rash and diarrhea than trial data may suggest. The speaker recommends proactive management with non-sedating antihistamines starting the day *before* therapy and prophylactic loperamide. This strategy, combined with dose reductions that don't compromise PFS, is key for patient tolerance.